CA2772621C - Methods and compositions for direct chemical lysis - Google Patents
Methods and compositions for direct chemical lysis Download PDFInfo
- Publication number
- CA2772621C CA2772621C CA2772621A CA2772621A CA2772621C CA 2772621 C CA2772621 C CA 2772621C CA 2772621 A CA2772621 A CA 2772621A CA 2772621 A CA2772621 A CA 2772621A CA 2772621 C CA2772621 C CA 2772621C
- Authority
- CA
- Canada
- Prior art keywords
- composition
- sample
- direct chemical
- chemical lysis
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 143
- 230000009089 cytolysis Effects 0.000 title claims abstract description 102
- 239000000126 substance Substances 0.000 title claims abstract description 78
- 238000000034 method Methods 0.000 title claims abstract description 53
- 239000000523 sample Substances 0.000 claims abstract description 112
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 72
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 72
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 72
- 239000000872 buffer Substances 0.000 claims abstract description 68
- 238000003556 assay Methods 0.000 claims abstract description 63
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 23
- 239000012472 biological sample Substances 0.000 claims abstract description 17
- 230000002934 lysing effect Effects 0.000 claims abstract description 4
- 239000003085 diluting agent Substances 0.000 claims description 110
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 72
- 239000011780 sodium chloride Substances 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 32
- 238000001514 detection method Methods 0.000 claims description 30
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 239000002736 nonionic surfactant Substances 0.000 claims description 20
- 229910052751 metal Inorganic materials 0.000 claims description 19
- 239000002184 metal Substances 0.000 claims description 19
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 16
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 14
- 239000000470 constituent Substances 0.000 claims description 13
- 230000003321 amplification Effects 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 12
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 11
- 239000000090 biomarker Substances 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 9
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 9
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 9
- 238000002965 ELISA Methods 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- 238000009007 Diagnostic Kit Methods 0.000 claims description 7
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 7
- 239000012188 paraffin wax Substances 0.000 claims description 7
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 108091006629 SLC13A2 Proteins 0.000 claims description 5
- 230000001413 cellular effect Effects 0.000 claims description 5
- ZPIRTVJRHUMMOI-UHFFFAOYSA-N octoxybenzene Chemical compound CCCCCCCCOC1=CC=CC=C1 ZPIRTVJRHUMMOI-UHFFFAOYSA-N 0.000 claims description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 4
- 235000011164 potassium chloride Nutrition 0.000 claims description 4
- 239000001103 potassium chloride Substances 0.000 claims description 4
- 239000001632 sodium acetate Substances 0.000 claims description 4
- 235000017281 sodium acetate Nutrition 0.000 claims description 4
- 238000001574 biopsy Methods 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- 244000007853 Sarothamnus scoparius Species 0.000 claims 1
- 235000019253 formic acid Nutrition 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims 1
- 229920001308 poly(aminoacid) Polymers 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 238000000605 extraction Methods 0.000 abstract description 58
- 108010067770 Endopeptidase K Proteins 0.000 abstract description 13
- 239000004094 surface-active agent Substances 0.000 abstract description 11
- 239000006163 transport media Substances 0.000 abstract description 5
- 238000005119 centrifugation Methods 0.000 abstract description 4
- 238000012986 modification Methods 0.000 abstract description 4
- 230000004048 modification Effects 0.000 abstract description 4
- 238000012545 processing Methods 0.000 abstract description 4
- 230000002035 prolonged effect Effects 0.000 abstract description 4
- 102000004190 Enzymes Human genes 0.000 abstract description 3
- 108090000790 Enzymes Proteins 0.000 abstract description 3
- 108091005461 Nucleic proteins Proteins 0.000 abstract description 3
- 108020004414 DNA Proteins 0.000 description 76
- 102000053602 DNA Human genes 0.000 description 76
- 210000004027 cell Anatomy 0.000 description 55
- 238000011534 incubation Methods 0.000 description 36
- 238000007400 DNA extraction Methods 0.000 description 27
- 241000271897 Viperidae Species 0.000 description 26
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 24
- 241000282414 Homo sapiens Species 0.000 description 18
- 238000003753 real-time PCR Methods 0.000 description 15
- 229920002477 rna polymer Polymers 0.000 description 14
- 229920004890 Triton X-100 Polymers 0.000 description 12
- 239000013504 Triton X-100 Substances 0.000 description 12
- 244000052769 pathogen Species 0.000 description 12
- 241000341655 Human papillomavirus type 16 Species 0.000 description 11
- 238000010828 elution Methods 0.000 description 11
- 238000006386 neutralization reaction Methods 0.000 description 11
- 206010041823 squamous cell carcinoma Diseases 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 206010008263 Cervical dysplasia Diseases 0.000 description 10
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 10
- 230000002411 adverse Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 8
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 8
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 7
- 239000007983 Tris buffer Substances 0.000 description 7
- 238000004132 cross linking Methods 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000700605 Viruses Species 0.000 description 6
- 101100468275 Caenorhabditis elegans rep-1 gene Proteins 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 5
- 230000003071 parasitic effect Effects 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100030960 DNA replication licensing factor MCM2 Human genes 0.000 description 2
- 102100033720 DNA replication licensing factor MCM6 Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000583807 Homo sapiens DNA replication licensing factor MCM2 Proteins 0.000 description 2
- 101001018484 Homo sapiens DNA replication licensing factor MCM6 Proteins 0.000 description 2
- 101001018431 Homo sapiens DNA replication licensing factor MCM7 Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 244000053095 fungal pathogen Species 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 244000052613 viral pathogen Species 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 244000000190 yeast pathogen Species 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000588780 Bordetella parapertussis Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 238000013382 DNA quantification Methods 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000733249 Homo sapiens Tumor suppressor ARF Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 240000004759 Inga spectabilis Species 0.000 description 1
- 101100238610 Mus musculus Msh3 gene Proteins 0.000 description 1
- 241000187482 Mycobacterium avium subsp. paratuberculosis Species 0.000 description 1
- 241000545499 Mycobacterium avium-intracellulare Species 0.000 description 1
- 241001302239 Mycobacterium tuberculosis complex Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 102100033254 Tumor suppressor ARF Human genes 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 235000019624 protein content Nutrition 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 102220243482 rs35799536 Human genes 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 108091029842 small nuclear ribonucleic acid Proteins 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/06—Lysis of microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/708—Specific hybridization probes for papilloma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Sampling And Sample Adjustment (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23955309P | 2009-09-03 | 2009-09-03 | |
| US61/239,553 | 2009-09-03 | ||
| PCT/US2010/047653 WO2011028887A2 (en) | 2009-09-03 | 2010-09-02 | Methods and compositions for direct chemical lysis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2772621A1 CA2772621A1 (en) | 2011-03-10 |
| CA2772621C true CA2772621C (en) | 2019-11-12 |
Family
ID=43648071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2772621A Active CA2772621C (en) | 2009-09-03 | 2010-09-02 | Methods and compositions for direct chemical lysis |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10190152B2 (enExample) |
| EP (1) | EP2473596B1 (enExample) |
| JP (1) | JP5916610B2 (enExample) |
| CN (1) | CN102575220B (enExample) |
| AU (1) | AU2010289430B2 (enExample) |
| BR (1) | BR112012004699B1 (enExample) |
| CA (1) | CA2772621C (enExample) |
| DK (1) | DK2473596T3 (enExample) |
| ES (1) | ES2660762T3 (enExample) |
| WO (1) | WO2011028887A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2473596T3 (en) * | 2009-09-03 | 2018-01-22 | Becton Dickinson Co | METHODS AND COMPOSITIONS FOR DIRECT CHEMICAL LYSIS |
| CN103421891B (zh) * | 2013-03-26 | 2016-03-02 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 一种用于PCR检测的血浆miRNA制备方法 |
| CA2961613A1 (en) * | 2014-09-17 | 2016-03-24 | Hologic, Inc. | Method of partial lysis and assay |
| CN104862305A (zh) * | 2015-06-17 | 2015-08-26 | 河南省农业科学院畜牧兽医研究所 | 一种用于动物组织基因组dna和rna快速提取试剂盒及提取方法和应用 |
| EP3222719B8 (en) * | 2016-03-24 | 2021-03-17 | Allflex Europe SAS | Use of an aqueous composition for dissolving biomolecules from a tissue sample |
| CN107723240A (zh) * | 2016-08-12 | 2018-02-23 | 微基生物科技（上海）有限公司 | 一种皮肤、口腔、生殖道样品中的微生物保存试剂及其制备方法和应用 |
| US10792416B2 (en) | 2017-05-30 | 2020-10-06 | Haemonetics Corporation | System and method for collecting plasma |
| CN118853827A (zh) | 2018-10-01 | 2024-10-29 | 贝克顿迪金森公司 | 确定5’转录物序列 |
| CN110272898B (zh) * | 2019-07-11 | 2023-06-09 | 上海市浦东新区疾病预防控制中心 | 一种通用型微生物病原体裂解液及其应用 |
| CN111057704B (zh) * | 2019-12-31 | 2022-07-05 | 广州市金圻睿生物科技有限责任公司 | 一种石蜡切片样本dna提取的脱蜡裂解结合液、试剂盒及方法 |
| CN115379793A (zh) * | 2020-04-21 | 2022-11-22 | 美国西门子医学诊断股份有限公司 | 用于临床样本采集和分子诊断应用的运送培养基及其生产和使用方法 |
| CN113957122B (zh) * | 2020-07-21 | 2024-01-26 | 厦门赛尔吉亚医学检验所有限公司 | 一种在宫颈细胞样本中提取dna的方法 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3689633A (en) | 1969-01-13 | 1972-09-05 | Teikoku Hormone Mfg Co Ltd | Preparation of test sample for immunological assay of pregnancy of mares |
| DE2532183C3 (de) | 1975-07-18 | 1982-03-04 | Behringwerke Ag, 3550 Marburg | Polyionische isotonische Salzlösung zur Konservierung von Erythrozyten oder zur Perfusion und zur Konservierung von zur Transplantion bestimmter Organen |
| US4333847A (en) | 1979-04-30 | 1982-06-08 | P. B. Macedo | Fixation by anion exchange of toxic materials in a glass matrix |
| US5248506A (en) | 1986-03-19 | 1993-09-28 | American National Red Cross | Synthetic, plasma-free, transfusible storage medium for red blood cells and platelets |
| GB8915759D0 (en) | 1989-07-10 | 1989-08-31 | Shandon Scient Ltd | Cell block preparation |
| US5231015A (en) * | 1989-10-18 | 1993-07-27 | Eastman Kodak Company | Methods of extracting nucleic acids and pcr amplification without using a proteolytic enzyme |
| US4997932A (en) | 1989-11-13 | 1991-03-05 | Boehringer Mannheim Corporation | Method and kit for purifying nucleic acids |
| US5136025A (en) | 1990-04-04 | 1992-08-04 | California Biotechnology Inc. | Method to purify basic fibroblast growth factor |
| US5700636A (en) | 1990-10-19 | 1997-12-23 | Becton Dickinson And Company | Methods for selectively detecting microorganisms associated with vaginal infections in complex biological samples |
| US5256571A (en) | 1991-05-01 | 1993-10-26 | Cytyc Corporation | Cell preservative solution |
| CA2218875C (en) | 1991-07-23 | 2000-11-07 | The Research Foundation Of State University Of New York | Improvements in the in situ pcr |
| AU664050B2 (en) | 1991-12-18 | 1995-11-02 | Becton Dickinson & Company | Process for lysing mycobacteria |
| DE69329353T2 (de) * | 1992-03-05 | 2001-01-04 | Becton Dickinson And Co., Franklin Lakes | Verfahren zur Herstellung und Analyse von Leukozyten in Vollblut unter Verwendung der Durchflusszytometrie |
| WO1994026867A1 (en) * | 1993-05-06 | 1994-11-24 | Abbott Laboratories | Direct lysis buffer and the detection of hiv-1 plasma viremia |
| CA2129773C (en) | 1993-09-02 | 2007-05-01 | Michael Klaus | Aromatic carboxylic acid derivatives |
| AU682538B2 (en) * | 1993-11-16 | 1997-10-09 | Becton Dickinson & Company | Process for lysing mycobacteria |
| WO1995014768A2 (en) | 1993-11-29 | 1995-06-01 | Gen-Probe Incorporated | Method for extracting nucleic acids from a wide range of organisms |
| US5545555A (en) | 1994-07-25 | 1996-08-13 | Microtest, Inc. | Microbial transport media |
| AU702896B2 (en) * | 1995-09-21 | 1999-03-11 | Becton Dickinson & Company | Detection of nucleic acids in cells by thermophilic strand displacement amplification |
| US5620869A (en) | 1995-09-28 | 1997-04-15 | Becton, Dickinson And Company | Methods for reducing inhibition of nucleic acid amplification reactions |
| WO1998016261A1 (en) | 1996-10-16 | 1998-04-23 | Enviro-Mate Pty. Ltd. | Method and apparatus for deodorisation and detoxification |
| JP2002508190A (ja) | 1997-12-12 | 2002-03-19 | ダイジーン・コーポレーション | 万能収集媒質 |
| US5958300A (en) | 1998-02-06 | 1999-09-28 | Genzyme Corporation | Composition for patient sample preparation |
| US6265164B1 (en) | 1998-03-26 | 2001-07-24 | Biochain Institute, Inc. | Compositions and methods for directly and rapidly analyzing the biochemical components of microorganisms |
| JPH11332562A (ja) * | 1998-04-28 | 1999-12-07 | Ortho Clinical Diagnostics Inc | 組織試料およびパラフィン包埋組織から核酸を抽出するための改良方法 |
| US6245568B1 (en) * | 1999-03-26 | 2001-06-12 | Merck & Co., Inc. | Human papilloma virus vaccine with disassembled and reassembled virus-like particles |
| WO2000060353A1 (en) | 1999-04-06 | 2000-10-12 | Genzyme Corporation | Composition for patient sample preparation |
| US6916608B2 (en) | 1999-09-10 | 2005-07-12 | Becton, Dickinson And Company | Composition for providing long term stability to cells for diagnostic testing |
| JP3580801B2 (ja) * | 2001-08-01 | 2004-10-27 | 富士写真フイルム株式会社 | 核酸の分離精製方法 |
| WO2003023062A2 (en) | 2001-09-13 | 2003-03-20 | Sonic Clinical Institute Pty Limited | Method of diagnosis for c.trachomatis infection using dna amplification assay on liquid cytology samples |
| US20050032105A1 (en) * | 2001-10-12 | 2005-02-10 | Bair Robert Jackson | Compositions and methods for using a solid support to purify DNA |
| RU2253430C2 (ru) * | 2002-03-19 | 2005-06-10 | Комкин Андрей Викторович | Устройство для пассивно-активной гимнастики пальцев "пальчиковый бассейн" |
| KR100633808B1 (ko) | 2002-05-21 | 2006-10-13 | 아크레이 가부시키가이샤 | 항산균의 용균 방법 및 그것을 사용한 유전자 증폭 또는검출 방법 |
| US20040022764A1 (en) * | 2002-07-31 | 2004-02-05 | Hanan Polansky | Inhibition of microcompetition with a foreign polynucleotide as treatment of chronic disease |
| US20040038213A1 (en) * | 2002-08-06 | 2004-02-26 | Kwon Jai W. | Genotyping by in situ PCR amplification of a polynucleotide in a tissue biopsy |
| JP2006507818A (ja) * | 2002-11-01 | 2006-03-09 | プロメガ コーポレイション | 細胞溶解のための組成物、使用方法、装置およびキット |
| JP2007516729A (ja) * | 2003-12-30 | 2007-06-28 | シグマ−アルドリッチ・カンパニー | 酵素消化による核酸の迅速な調製 |
| WO2005121373A2 (en) | 2004-06-03 | 2005-12-22 | Advandx, Inc. | Hybridization of pna probes in alcohol solutions |
| AU2005277527A1 (en) * | 2004-08-18 | 2006-03-02 | Preanalytix Gmbh | Additive, method, and article for DNA collection, stabilization, and purification |
| WO2006047481A2 (en) * | 2004-10-22 | 2006-05-04 | Redpath Integrated Pathology, Inc. | Enhanced amplifiability of minute fixative-treated tissue samples, minute stained cytology samples, and other minute sources of dna |
| EP1809744B1 (en) * | 2004-11-05 | 2018-06-06 | QIAGEN North American Holdings, Inc. | Compositions and methods for purifying nucleic acids from stabilization reagents |
| DE102004055615A1 (de) | 2004-11-16 | 2006-05-18 | Universitätsklinikum Hamburg-Eppendorf | In vitro aus Knochenmarkstammzellen differenzierte Retina-spezifische Zellen, ihre Herstellung und Verwendung |
| CA2604135A1 (en) | 2005-04-07 | 2006-10-19 | University Of South Florida | Pop2 nfkb-inhibiting polypeptides, nucleic acids and methods of use |
| US9243241B2 (en) * | 2005-05-31 | 2016-01-26 | Life Technologies Corporation | Separation and purification of nucleic acid from paraffin-containing samples |
| US20060286557A1 (en) * | 2005-06-15 | 2006-12-21 | Basehore Lee S | Combined lysis and PCR buffer |
| JP2007117084A (ja) | 2005-09-28 | 2007-05-17 | Fujifilm Corp | 核酸抽出法 |
| JP2008043332A (ja) | 2006-08-17 | 2008-02-28 | Panomics Inc | 組織スライドからの核酸定量 |
| ES2552858T3 (es) * | 2007-10-01 | 2015-12-02 | Longhorn Vaccines And Diagnostics, Llc | Recogida de muestras biológicas y sistema de transporte y métodos de uso |
| US9207240B2 (en) * | 2007-11-14 | 2015-12-08 | Arbor Vita Corporation | Method of efficient extraction of protein from cells |
| DE102008026058A1 (de) * | 2008-05-30 | 2009-12-03 | Qiagen Gmbh | Lyse, Binde- und/oder Waschreagenz verwendbar zur Isolierung und/oder Reinigung von Nukleinsäuren |
| DK2473596T3 (en) * | 2009-09-03 | 2018-01-22 | Becton Dickinson Co | METHODS AND COMPOSITIONS FOR DIRECT CHEMICAL LYSIS |
| AU2010291990B2 (en) * | 2009-09-14 | 2016-05-05 | Qiagen Gaithersburg, Inc. | Compositions and methods for recovery of nucleic acids or proteins from tissue samples fixed in cytology media |
-
2010
- 2010-09-02 DK DK10814484.1T patent/DK2473596T3/en active
- 2010-09-02 WO PCT/US2010/047653 patent/WO2011028887A2/en not_active Ceased
- 2010-09-02 BR BR112012004699-3A patent/BR112012004699B1/pt active IP Right Grant
- 2010-09-02 CA CA2772621A patent/CA2772621C/en active Active
- 2010-09-02 US US12/874,602 patent/US10190152B2/en active Active
- 2010-09-02 ES ES10814484.1T patent/ES2660762T3/es active Active
- 2010-09-02 JP JP2012528040A patent/JP5916610B2/ja active Active
- 2010-09-02 CN CN201080046134.7A patent/CN102575220B/zh active Active
- 2010-09-02 EP EP10814484.1A patent/EP2473596B1/en active Active
- 2010-09-02 AU AU2010289430A patent/AU2010289430B2/en active Active
-
2016
- 2016-03-11 US US15/067,428 patent/US10323267B2/en active Active
-
2019
- 2019-04-30 US US16/399,305 patent/US11434519B2/en active Active
-
2022
- 2022-08-08 US US17/883,403 patent/US20220372554A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US10190152B2 (en) | 2019-01-29 |
| JP5916610B2 (ja) | 2016-05-11 |
| BR112012004699A2 (pt) | 2015-09-01 |
| CA2772621A1 (en) | 2011-03-10 |
| US11434519B2 (en) | 2022-09-06 |
| US20110059455A1 (en) | 2011-03-10 |
| EP2473596A4 (en) | 2013-01-16 |
| WO2011028887A2 (en) | 2011-03-10 |
| BR112012004699B1 (pt) | 2019-10-15 |
| AU2010289430B2 (en) | 2015-06-25 |
| AU2010289430A1 (en) | 2012-03-22 |
| DK2473596T3 (en) | 2018-01-22 |
| US10323267B2 (en) | 2019-06-18 |
| JP2013503639A (ja) | 2013-02-04 |
| US20220372554A1 (en) | 2022-11-24 |
| ES2660762T3 (es) | 2018-03-26 |
| US20190256893A1 (en) | 2019-08-22 |
| EP2473596A2 (en) | 2012-07-11 |
| WO2011028887A3 (en) | 2011-07-28 |
| EP2473596B1 (en) | 2017-12-13 |
| US20160194687A1 (en) | 2016-07-07 |
| CN102575220A (zh) | 2012-07-11 |
| CN102575220B (zh) | 2015-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220372554A1 (en) | Methods and compositions for direct chemical lysis | |
| CN108823282B (zh) | 一种样本核酸检测试剂盒、试剂及其应用 | |
| JP2019068818A (ja) | 目的の核酸の特異的な単離方法 | |
| US20040115689A1 (en) | Method and device for collecting and stabilizing a biological sample | |
| JP2015119719A (ja) | 迅速に結果を得るハイブリッドキャプチャー法によるアッセイおよびシステム | |
| JP2012506705A5 (enExample) | ||
| CN108410951B (zh) | 一种新的核酸提取试剂及其应用 | |
| JP6559647B2 (ja) | 非溶出試料のワンステップ核酸増幅方法 | |
| US9822404B2 (en) | Control for diagnostic assay | |
| JP2016514464A (ja) | 生物試料の安定化 | |
| US20250122557A1 (en) | Mitochondrial nucleic acid depletion and detection | |
| JP2016501011A (ja) | 非溶出試料の一段階核酸増幅法 | |
| JP2025109742A (ja) | ホルムアルデヒドを含有する液体系細胞診用保存剤中検体から核酸を単離する方法 | |
| Thatcher | Nucleic acid isolation | |
| JP2018508239A (ja) | 核酸の単離 | |
| EP1777291A1 (en) | Method for the isolation of mRNA from formalin fixed, paraffin-embedded tissue | |
| WO2013117968A1 (en) | Methods for lysing bacteria from sample and isolating cellular components therefrom, and kits therefor | |
| Zainabadi et al. | An efficient and cost-effective method for purification of small sized DNAs and RNAs from human urine Repeat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |